...
首页> 外文期刊>Journal of Obstetrics and Gynecology of India >Safety and Efficacy of Oral Mifepristone in Pre-induction Cervical Ripening and Induction of Labour in Prolonged Pregnancy
【24h】

Safety and Efficacy of Oral Mifepristone in Pre-induction Cervical Ripening and Induction of Labour in Prolonged Pregnancy

机译:米非司酮口服在宫颈早孕和长时间引产中的安全性和有效性

获取原文

摘要

Objective(S) To study the safety and efficacy of oral mifepristone in pre-induction cervical ripening and induction of labour in prolonged pregnancy. Method(S) This is a single blind randomized control trial. 100 women with prolonged pregnancy beyond 40?weeks and Bishop score <6 were recruited, and randomly allocated into two groups. Women who received Tab. Mifepristone 200?mg orally were assigned in Study Group ( n =?50) and who received placebo orally were assigned in Control Group ( n =?50) At the end of 24?h, change in the Bishop’s score was assessed and Tab. Misoprostol 25?μg was administered intravaginally every 4?h, maximum 6 doses for induction/augmentation of labour. Analysis regarding safety and efficacy of the drug was done with regards to maternal and perinatal outcome. Result(S) Among 100 subjects, 50 received mifepristone and 50 received placebo. Mean induction to delivery interval was 1,907?±?368.4?min for Study Group versus 2,079?±?231.6?min for Control Group. The improvement in mean Bishop score was 5.0408?±?1.90 for Study Group compared with 3.26?±?1.15 was for Control Group after 24?h. Mean dose of misoprostol in Study Group was 40?±?27.2, while the same in Control Group was 52?±?19.46. Eight (16?%) women in Study Group and two (4?%) women in Control Group delivered vaginally within 24?h without any need of augmentation. There were 6 (12?%) cesareans and 2 (4?%) instrumental deliveries in Study Group and 8 (16?%) cesareans and 5 (10?%) instrumental deliveries in the Control Group. There was no statistically significant difference in perinatal outcomes between two groups. Conclusion(S) Mifepristone had a modest effect on cervical ripening when given 24?h prior to labour induction and appearing to reduce need for misoprostol compared with placebo.
机译:目的研究口服米非司酮在长时间妊娠中诱导宫颈成熟和引产的安全性和有效性。方法这是一项单盲随机对照试验。招募了100名怀孕时间超过40周且Bishop得分<6的妇女,并随机分为两组。接受Tab的女性。在研究组中口服米非司酮200 mg(n = 50),在对照组中口服安慰剂的米非司酮(n = 50)。在24 h结束时,评估Bishop得分的变化并按Tab进行。每4?h阴道内注射25?μg米索前列醇,最大6剂剂量用于引产/增强分娩。关于药物的安全性和有效性的分析已针对孕产妇和围产期结局进行了。结果在100名受试者中,有50名接受了米非司酮和50名接受了安慰剂。研究组对分娩间隔的平均诱导为1,907±±368.4μmin,对照组为2,079±±231.6μmin。 24小时后,研究组的Bishop平均得分提高了5.0408±1.09,而对照组的平均Bishop得分为3.26±1.15。研究组米索前列醇的平均剂量为40?±?27.2,而对照组的平均剂量为52?±?19.46。研究组中有8名(16%)妇女,对照组中有2名(4 %%)妇女在24小时内阴道分娩,无需增加。在研究组中,有6(12%)剖宫产和2(4 %%)剖宫产,在对照组中有8(16 %%)剖宫产和5(10 %%)剖宫产。两组的围产期结局差异无统计学意义。结论米非司酮在引产前24小时给予子宫颈成熟有中等程度的作用,与安慰剂相比,米索前列酮似乎减少了米索前列醇的需要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号